Pfizer pays $1.3 billion to gain control of Exubera rights
Pfizer will pay Sanofi-Aventis $1.3 billion to acquire worldwide rights to the inhaled human insulin Exubera, a product both companies ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.